DexCom, Inc. (NASDAQ:DXCM) Stake Lessened by Atria Investments Inc

Atria Investments Inc trimmed its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 41.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 15,320 shares of the medical device company’s stock after selling 11,000 shares during the quarter. Atria Investments Inc’s holdings in DexCom were worth $1,027,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in DXCM. Avantax Advisory Services Inc. grew its stake in DexCom by 35.4% in the first quarter. Avantax Advisory Services Inc. now owns 3,601 shares of the medical device company’s stock worth $499,000 after purchasing an additional 942 shares in the last quarter. Orion Portfolio Solutions LLC raised its position in shares of DexCom by 31.9% during the 1st quarter. Orion Portfolio Solutions LLC now owns 9,871 shares of the medical device company’s stock valued at $1,369,000 after acquiring an additional 2,388 shares in the last quarter. Intech Investment Management LLC bought a new position in DexCom during the first quarter worth $2,575,000. Acadian Asset Management LLC boosted its holdings in DexCom by 40.3% in the first quarter. Acadian Asset Management LLC now owns 8,008 shares of the medical device company’s stock worth $1,109,000 after purchasing an additional 2,299 shares during the period. Finally, O Shaughnessy Asset Management LLC increased its stake in DexCom by 25.5% during the first quarter. O Shaughnessy Asset Management LLC now owns 22,027 shares of the medical device company’s stock valued at $3,055,000 after purchasing an additional 4,481 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Price Performance

NASDAQ DXCM opened at $75.88 on Monday. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The firm has a market capitalization of $29.64 billion, a PE ratio of 45.44, a P/E/G ratio of 2.33 and a beta of 1.17. The company’s 50 day simple moving average is $70.03 and its 200 day simple moving average is $91.42. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. Sanford C. Bernstein raised their price target on shares of DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a research report on Friday, October 25th. Barclays decreased their target price on DexCom from $138.00 to $113.00 and set an “equal weight” rating for the company in a research note on Monday, July 29th. BTIG Research cut their price target on DexCom from $156.00 to $120.00 and set a “buy” rating on the stock in a report on Friday, July 26th. StockNews.com downgraded DexCom from a “buy” rating to a “hold” rating in a research note on Saturday, November 2nd. Finally, Robert W. Baird raised their target price on DexCom from $80.00 to $82.00 and gave the company a “neutral” rating in a research note on Monday, August 5th. Seven equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $104.59.

Insider Activity

In related news, EVP Sadie Stern sold 426 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the sale, the executive vice president now directly owns 75,451 shares in the company, valued at approximately $5,217,436.65. This trade represents a 0.56 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Jacob Steven Leach sold 746 shares of the company’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the transaction, the chief operating officer now directly owns 264,915 shares in the company, valued at $18,318,872.25. This represents a 0.28 % decrease in their position. The disclosure for this sale can be found here. 0.30% of the stock is owned by insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.